Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1804503
Original Article

Stereotactic Body Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Observational Study from a Regional Cancer Center in South Asia—A Case Series

Arunkumar M.N 
1   Department of Radiation Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Priyadarshini V.
1   Department of Radiation Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Gangothri Selvarajan
2   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Ramakrishnan Ayloor Seshadri
3   Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Pradeep Jeyakumar S.
3   Department of Surgical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction Concurrent chemoradiation is the treatment of choice for unresectable locally advanced pancreatic cancer (LAPC). Recent progress toward an effective chemotherapeutic regime has seen improvement in systemic control; however, local control remains a significant issue. One strategy to improve local control and survival is stereotactic body radiotherapy (SBRT).

Objectives This study aims to describe the clinical and treatment characteristics of patients with unresectable LAPC treated with SBRT and to assess the outcome.

Material and Methods This is a retrospective observation study of case series involving patients treated with SBRT from January 2015 to December 2023 with unresectable LAPC. Data were recorded from the electronic medical records of the hospital-based cancer registry, and overall survival was calculated using the Statistical Package for the Social Sciences software.

Result We enrolled four patients in this study. This group consisted of four patients with unresectable LAPC who were treated with the FOLFORINOX (folinic acid, fluorouracil, irinotecan, and oxaliplatin) chemotherapy regime followed by SBRT. For most patients, the radiotherapy dose was 30 to 40 Gy five times per week. These patients exhibited no acute or late toxicity, with 5 to 18 months overall survival.

Conclusion Chemotherapy followed by SBRT is an effective treatment in unresectable LAPC besides chemoradiation.

Keywords

unresectable pancreatic cancer - SBRT - locally advanced - chemotherapy

Institutional Review Board

Approved.


Authors' Contributions

A.M.N., P.V., G.S., R.A., P.J.S contributed to the Concepts design, definition of intellectual content, and manuscript review. A.M.N., P.V. contributed to the literature search, data acquisition, data analysis, manuscript preparation, manuscript editing. A.M.N. contributed to the statistical analysis and as guarantor.


Patient Consent

None.




Publication History

Article published online:
20 February 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedSearch in Google Scholar
  • 2 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63 (1) 11-30
    CrossrefPubMedSearch in Google Scholar
  • 3 Hammel P, Huguet F, van Laethem JL. et al; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016; 315 (17) 1844-1853
    CrossrefPubMedSearch in Google Scholar
  • 4 Chakraborty S, Singh S. Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study. Ann Gastroenterol 2013; 26 (04) 346-352
    PubMedSearch in Google Scholar
  • 5 Haddock MG, Swaminathan R, Foster NR. et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol 2007; 25 (18) 2567-2572
    CrossrefPubMedSearch in Google Scholar
  • 6 Willett CG, Czito BG, Bendell JC, Ryan DP. Locally advanced pancreatic cancer. J Clin Oncol 2005; 23 (20) 4538-4544
    CrossrefPubMedSearch in Google Scholar
  • 7 Toesca DAS, Koong AJ, Poultsides GA. et al. Management of borderline resectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2018; 100 (05) 1155-1174
    CrossrefPubMedSearch in Google Scholar
  • 8 Small Jr W, Berlin J, Freedman GM. et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008; 26 (06) 942-947
    CrossrefPubMedSearch in Google Scholar
  • 9 Shinchi H, Takao S, Noma H. et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53 (01) 146-150
    CrossrefPubMedSearch in Google Scholar
  • 10 FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer | New England Journal of Medicine. Accessed October 16, 2024 at: https://www.nejm.org/doi/full/10.1056/NEJMoa1011923
  • 11 Von Hoff DD, Ervin T, Arena FP. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369 (18) 1691-1703
    CrossrefPubMedSearch in Google Scholar
  • 12 Mukherjee S, Hurt CN, Bridgewater J. et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14 (04) 317-326
    CrossrefPubMedSearch in Google Scholar
  • 13 Underberg RWM, Lagerwaard FJ, Cuijpers JP, Slotman BJ, van Sörnsen de Koste JR, Senan S. Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer. Int J Radiat Oncol Biol Phys 2004; 60 (04) 1283-1290
    CrossrefPubMedSearch in Google Scholar
  • 14 Underberg RWM, Lagerwaard FJ, Slotman BJ, Cuijpers JP, Senan S. Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer. Int J Radiat Oncol Biol Phys 2005; 63 (01) 253-260
    CrossrefPubMedSearch in Google Scholar
  • 15 Glide-Hurst CK, Chetty IJ. Improving radiotherapy planning, delivery accuracy, and normal tissue sparing using cutting edge technologies. J Thorac Dis 2014; 6 (04) 303-318
    PubMedSearch in Google Scholar
  • 16 Oar A, Lee M, Le H. et al. Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) guidelines for pancreatic stereotactic body radiation therapy (SBRT). Pract Radiat Oncol 2020; 10 (03) e136-e146
    CrossrefPubMedSearch in Google Scholar
  • 17 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedSearch in Google Scholar
  • 18 Bilimoria KY, Bentrem DJ, Ko CY. et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer 2007; 110 (04) 738-744
    CrossrefPubMedSearch in Google Scholar
  • 19 Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80 (10) 751-755
    CrossrefPubMedSearch in Google Scholar
  • 20 Koong AC, Christofferson E, Le QT. et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63 (02) 320-323
    CrossrefPubMedSearch in Google Scholar
  • 21 Koong AC, Le QT, Ho A. et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 58 (04) 1017-1021
    CrossrefPubMedSearch in Google Scholar
  • 22 Schellenberg D, Kim J, Christman-Skieller C. et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011; 81 (01) 181-188
    CrossrefPubMedSearch in Google Scholar
  • 23 Schellenberg D, Goodman KA, Lee F. et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008; 72 (03) 678-686
    CrossrefPubMedSearch in Google Scholar
  • 24 Gnanaguru V, Dhanushkodi M, Radhakrishnan V. et al. Induction chemotherapy in locally advanced head-and-neck squamous cell carcinoma: real-world outcome. Oncol J India 2020; 4 (03) 105
    CrossrefSearch in Google Scholar
  • 25 Hosein PJ, Macintyre J, Kawamura C. et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12 (01) 199
    CrossrefPubMedSearch in Google Scholar
  • 26 Faris JE, Blaszkowsky LS, McDermott S. et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013; 18 (05) 543-548
    CrossrefPubMedSearch in Google Scholar
  • 27 Comito T, Massaro M, Teriaca MA. et al. Can stereotactic body radiation therapy (SBRT) improve the prognosis of unresectable locally advanced pancreatic cancer? Long-term clinical outcomes, toxicity and prognostic factors on 142 patients (STEP study). Curr Oncol 2023; 30 (07) 7073-7088
    CrossrefPubMedSearch in Google Scholar
  • 28 de Geus SWL, Eskander MF, Kasumova GG. et al. Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review. Cancer 2017; 123 (21) 4158-4167
    CrossrefPubMedSearch in Google Scholar
  • 29 Palta M, Godfrey D, Goodman KA. et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol 2019; 9 (05) 322-332
    CrossrefPubMedSearch in Google Scholar
  • 30 Pollom EL, Alagappan M, von Eyben R. et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Int J Radiat Oncol Biol Phys 2014; 90 (04) 918-925
    CrossrefPubMedSearch in Google Scholar
  • 31 Zhu X, Ju X, Cao Y. et al. Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: implications of target volume design. Int J Radiat Oncol Biol Phys 2019; 104 (01) 101-110
    CrossrefPubMedSearch in Google Scholar
  • 32 Colbert LE, Rebueno N, Moningi S. et al. Dose escalation for locally advanced pancreatic cancer: how high can we go?. Adv Radiat Oncol 2018; 3 (04) 693-700
    CrossrefPubMedSearch in Google Scholar
  • 33 Mazzarotto R, Simoni N, Guariglia S. et al. Dosimetric feasibility study of dose escalated stereotactic body radiation therapy (SBRT) in locally advanced pancreatic cancer (LAPC) patients: it is time to raise the bar. Front Oncol 2020; 10: 600940
    CrossrefPubMedSearch in Google Scholar